What adjuvant therapy would you recommend for a young premenopausal patient with TNBC and residual disease at surgery after completing neoadjuvant chemo with ddAC followed by dd paclitaxel, carboplatin, and pembrolizumab?

Community
Company
News
Contact Us
Sign in

Topics: Breast Cancer • Medical Oncology • Triple negative

Would you finish up pembrolizumab, give capecitabine, or both?

Related Questions

What would be your treatment approach in a premenopausal BRCA2+ patient with cT2N0 grade 2-3, ER negative, PR variably positive (30%; staining weak to high), HER2 negative breast cancer?

What is your preferred adjuvant chemotherapy regimen for a patient with local recurrence of TNBC two years after completing neoadjuvant ddAC-T who declined prior adjuvant capecitabine?

Would you offer neoadjuvant chemoimmunotherapy per KEYNOTE 522 for a patient with clinical stage IIB triple-negative breast cancer with apocrine histology or recommend surgery first?

How would you treat a patient with TNBC with a residual strongly PR+, ER- breast mass on mastectomy after neoadjuvant KEYNOTE 522 based chemoimmunotherapy?

Would you avoid chemotherapy in a postmenopausal woman (age 65+) with HR+/HER2 negative, breast cancer, T3, with Oncotype DX < 25?

What neoadjuvant chemotherapy regimen would you choose for a triple positive (ER+/PR+/HER2+) cT2N1 G3 breast cancer for an elderly patient (80 y/o)?

Would you consider chemoimmunotherapy (CP-Pembro-AC) in triple negative breast cancer if tumor is not palpable on physical exam?

Do you offer adjuvant abemaciclib to a high risk young patient desiring more children?

Would you offer capivasertib+fulvestrant in a patient with metastatic HR+ HER2 negative breast cancer with PTEN mutation who has progressed on fulvestrant plus ribociclib?

When do you consider the addition of concurrent pembrolizumab to breast irradiation?